| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/WNF.0000000000000073 |
| P698 | PubMed publication ID | 25768849 |
| P50 | author | Yoshikuni Mizuno | Q64858705 |
| P2093 | author name string | Tomoyoshi Kondo | |
| Japanese Istradefylline Study Group | |||
| P433 | issue | 2 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 41-46 | |
| P577 | publication date | 2015-03-01 | |
| P1433 | published in | Clinical Neuropharmacology | Q15753218 |
| P1476 | title | A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. | |
| P478 | volume | 38 |
| Q38691042 | Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration. |
| Q55297865 | Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges. |
| Q42372900 | Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder. |
| Q47751959 | Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners |
| Q39076762 | CK2-An Emerging Target for Neurological and Psychiatric Disorders |
| Q55286065 | Clinimetrics of the 9- and 19-Item Wearing-Off Questionnaire: A Systematic Review. |
| Q61453872 | Computational Studies Applied to Flavonoids against Alzheimer's and Parkinson's Diseases |
| Q38658203 | Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease |
| Q87945516 | Cyclic AMP-producing chemogenetic activation of indirect pathway striatal projection neurons and the downstream effects on the globus pallidus and subthalamic nucleus in freely moving mice |
| Q50917169 | Design, synthesis and evaluation of 2-aryl benzoxazoles as promising hit for the A2A receptor. |
| Q42322627 | Dopamine-Induced Changes in Gαolf Protein Levels in Striatonigral and Striatopallidal Medium Spiny Neurons Underlie the Genesis of l-DOPA-Induced Dyskinesia in Parkinsonian Mice |
| Q48020769 | Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects |
| Q64226635 | Fast, Efficient, and Versatile Synthesis of 6-amino-5-carboxamidouracils as Precursors for 8-Substituted Xanthines |
| Q92620973 | Gender-dependent effect of coffee consumption on tremor severity in de novo Parkinson's disease |
| Q91569639 | Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo |
| Q38882782 | How does adenosine control neuronal dysfunction and neurodegeneration? |
| Q47443548 | Istradefylline reduces memory deficits in aging mice with amyloid pathology |
| Q90745434 | Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson's Disease |
| Q61784879 | Neuronal adenosine A receptor overexpression is neuroprotective towards 3-nitropropionic acid-induced striatal toxicity: a rat model of Huntington's disease |
| Q38718194 | New and emerging medical therapies in Parkinson's disease |
| Q38570434 | New treatments for levodopa-induced motor complications |
| Q39229450 | Non-human primate models of PD to test novel therapies |
| Q38845546 | Nondopaminergic treatments for Parkinson's disease: current and future prospects |
| Q58587583 | PBF509, an Adenosine A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders |
| Q38765118 | Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging |
| Q92719134 | Potentiation of cannabinoid signaling in microglia by adenosine A2A receptor antagonists |
| Q34554401 | Recent advances in treating Parkinson's disease |
| Q64901815 | Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. |
| Q38843185 | Safety issues of compounds acting on adenosinergic signalling |
| Q47105024 | Striatal Gαolf/cAMP Signal-Dependent Mechanism to Generate Levodopa-Induced Dyskinesia in Parkinson's Disease |
| Q91739683 | Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody |
| Q47138950 | The effect of istradefylline for Parkinson's disease: A meta-analysis |
| Q30244421 | The epidemiology of Parkinson's disease: risk factors and prevention |
| Q64859188 | Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs |
Search more.